MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
MangoRx (NASDAQ: MGRX) has launched TRIM, a compounded oral dissolvable Tirzepatide tablet for weight loss, priced at $399 per month. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant weight loss results in clinical trials, with participants achieving 15-20% weight reduction in 72 weeks and up to 25% in 88 weeks. The TRIM formulation offers a convenient alternative to injectable therapies, aligning with the growing demand for non-invasive weight management solutions.
MangoRx's CEO, Jacob Cohen, emphasized the product's innovation and potential to meet changing patient needs. The company now offers both Tirzepatide (TRIM) and Semaglutide (SLIM) options for weight loss through its telemedicine platform. This launch positions MangoRx to capitalize on the expanding GLP-1 market, projected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with the obesity segment expected to dominate.
MangoRx (NASDAQ: MGRX) ha lanciato TRIM, una compressa orale discioglibile di Tirzepatide per la perdita di peso, con un prezzo di 399 dollari al mese. Il Tirzepatide, un agonista del recettore GIP e GLP-1, ha mostrato risultati significativi nella perdita di peso negli studi clinici, con i partecipanti che ottenevano una riduzione del peso del 15-20% in 72 settimane e fino al 25% in 88 settimane. La formulazione TRIM offre un'alternativa conveniente alle terapie iniettabili, in linea con la crescente domanda di soluzioni per la gestione del peso non invasive.
Il CEO di MangoRx, Jacob Cohen, ha sottolineato l'innovazione del prodotto e il suo potenziale per soddisfare le esigenze in evoluzione dei pazienti. L'azienda ora offre sia Tirzepatide (TRIM) che Semaglutide (SLIM) come opzioni per la perdita di peso tramite la sua piattaforma di telemedicina. Questo lancio posiziona MangoRx per sfruttare il mercato crescente dei GLP-1, previsto crescere da 49,3 miliardi di dollari nel 2024 a 157,5 miliardi di dollari entro il 2035, con il segmento dell'obesità che dovrebbe dominare.
MangoRx (NASDAQ: MGRX) ha lanzado TRIM, una tableta oral disoluble de Tirzepatide para la pérdida de peso, con un precio de 399 dólares al mes. Tirzepatide, un agonista dual de los receptores GIP y GLP-1, ha mostrado resultados significativos de pérdida de peso en ensayos clínicos, con participantes logrando una reducción de peso del 15-20% en 72 semanas y hasta 25% en 88 semanas. La formulación TRIM ofrece una alternativa conveniente a las terapias inyectables, alineándose con la creciente demanda de soluciones no invasivas para el manejo del peso.
El CEO de MangoRx, Jacob Cohen, enfatizó la innovación del producto y su potencial para satisfacer las necesidades cambiantes de los pacientes. La compañía ahora ofrece opciones de pérdida de peso tanto con Tirzepatide (TRIM) como con Semaglutide (SLIM) a través de su plataforma de telemedicina. Este lanzamiento posiciona a MangoRx para capitalizar el creciente mercado de GLP-1, que se prevé que crezca de 49.3 mil millones de dólares en 2024 a 157.5 mil millones de dólares para 2035, con el segmento de la obesidad que se espera domine.
MangoRx(NASDAQ: MGRX)가 TRIM을 출시했습니다. 이는 체중 감소를 위한 타르제파타이드(Tirzepatide) 복합 경구용 용해 테블릿으로, 가격은 한 달에 399달러입니다. 타르제파타이드는 이중 GIP 및 GLP-1 수용체 작용제로, 임상 시험에서 상당한 체중 감소 결과를 보여주었으며, 참가자들은 72주 동안 15-20%의 체중 감소와 88주 동안 최대 25%의 체중 감소를 달성했습니다. TRIM 제형은 주사 요법에 대한 편리한 대안을 제시하며, 비침습적인 체중 관리 솔루션에 대한 수요 증가에 부합합니다.
MangoRx의 CEO인 제이콥 코헨(Jacob Cohen)은 제품의 혁신성과 변화하는 환자의 요구를 충족할 가능성을 강조했습니다. 이 회사는 현재 티르제파타이드(TRIM)와 세마글루타이드(SLIM) 두 가지 체중 감소 옵션을 원격 의료 플랫폼을 통해 제공합니다. 이번 출시는 MangoRx가 2024년에 493억 달러에서 2035년까지 1575억 달러로 성장할 것으로 예상되는 GLP-1 시장의 확대를 활용할 수 있는 기회를 제공합니다. 여기서 비만 세그먼트가 주도할 것으로 예상됩니다.
MangoRx (NASDAQ: MGRX) a lancé TRIM, un comprimé oral dissous de Tirzepatide destiné à la perte de poids, à un prix de 399 dollars par mois. Le Tirzepatide, un agoniste des récepteurs GIP et GLP-1, a montré des résultats significatifs de perte de poids lors d'essais cliniques, les participants atteignant une réduction de poids de 15-20% en 72 semaines et jusqu'à 25% en 88 semaines. La formulation TRIM offre une alternative pratique aux thérapies injectables, en phase avec la demande croissante de solutions non invasives pour la gestion du poids.
Le PDG de MangoRx, Jacob Cohen, a souligné l'innovation du produit et son potentiel à répondre aux besoins changeants des patients. L'entreprise propose maintenant des options de perte de poids à la fois avec Tirzepatide (TRIM) et Semaglutide (SLIM) via sa plateforme de télémédecine. Ce lancement positionne MangoRx pour tirer parti du marché croissant des GLP-1, qui devrait passer de 49,3 milliards de dollars en 2024 à 157,5 milliards de dollars d'ici 2035, le segment de l'obésité devant dominer.
MangoRx (NASDAQ: MGRX) hat TRIM eingeführt, eine kombinierte orale lösliche Tirzepatid-Tablette zur Gewichtsreduktion, die 399 Dollar pro Monat kostet. Tirzepatid, ein dualer GIP- und GLP-1-Rezeptor-Agonist, hat in klinischen Studien signifikante Ergebnisse bei der Gewichtsreduktion gezeigt, wobei die Teilnehmer eine Gewichtsreduktion von 15-20% in 72 Wochen und bis zu 25% in 88 Wochen erzielten. Die TRIM-Formulierung bietet eine praktische Alternative zu injizierbaren Therapien, die mit der wachsenden Nachfrage nach nicht-invasiven Lösungen zur Gewichtsreduktion übereinstimmt.
Der CEO von MangoRx, Jacob Cohen, betonte die Innovationskraft des Produkts sowie dessen Potenzial, sich an die sich verändernden Bedürfnisse der Patienten anzupassen. Das Unternehmen bietet nun sowohl Tirzepatid (TRIM) als auch Semaglutid (SLIM) als Optionen zur Gewichtsreduktion über seine Telemedizin-Plattform an. Mit diesem Markteintritt positioniert sich MangoRx, um von dem wachsenden GLP-1-Markt zu profitieren, der voraussichtlich von 49,3 Milliarden Dollar im Jahr 2024 auf 157,5 Milliarden Dollar bis 2035 wachsen wird, wobei das Segment der Fettleibigkeit voraussichtlich dominieren wird.
- Launch of TRIM, an oral Tirzepatide tablet, expanding product portfolio
- Clinical trials show Tirzepatide can deliver up to 25% weight reduction
- Priced at $399 per month, offering a competitive alternative to injections
- Positioning in the growing GLP-1 market, projected to reach $157.5 billion by 2035
- Expanded offering with both Tirzepatide (TRIM) and Semaglutide (SLIM) options
- None.
Insights
The introduction of TRIM, an oral dissolvable Tirzepatide tablet, represents a significant advancement in the GLP-1 receptor agonist market. Clinical trials have demonstrated Tirzepatide's impressive efficacy, with patients achieving up to
MangoRx's oral formulation addresses a key patient need by eliminating injections, potentially improving adherence and expanding the addressable market. With both Tirzepatide (TRIM) and Semaglutide (SLIM) options now available, MangoRx is well-positioned in the rapidly growing GLP-1 market, projected to reach
However, the
MangoRx's launch of TRIM represents a strategic move to capitalize on the booming GLP-1 receptor agonist market. With a projected CAGR of
However, investors should consider MangoRx's current market cap of just over
While the product launch is promising, financial metrics such as revenue projections, profit margins and cash burn rate will be essential to evaluate the company's long-term viability and potential return on investment. The stock may see increased volatility as the market assesses the impact of this new product on MangoRx's growth trajectory.
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to
Further, in the SURMOUNT-4 trial, Tirzepatide not only helped patients achieve substantial weight loss, but it also helped patients maintain their progress over an extended period. After 88 weeks of treatment, patients experienced a total weight reduction of up to
MangoRx’s TRIM formulation now provides Tirzepatide treatment in an easy-to-use oral dissolvable tablet, eliminating the need for injections and enhancing patient convenience.
The launch of TRIM is a key strategic move for MangoRx, as the Company looks to strengthen its foothold in the expanding weight management sector. As demand for non-invasive, clinically proven solutions rises, we believe MangoRx is positioned to capitalize on this market growth.
Jacob Cohen, CEO and Founder of MangoRx, stated, “We are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections. TRIM’s introduction marks another significant step for MangoRx as we continue to innovate and meet the changing needs of patients. By launching TRIM, we are delivering a solution that enhances patient convenience without sacrificing efficacy. As demand for GLP-1-based treatments continues to climb, our telemedicine platform ensures that patients have access to safe, reliable options.”
According to a study performed by Roots Analysis, the global GLP-1 market is projected to grow from
With the addition of TRIM, MangoRx now offers patients both Tirzepatide and Semaglutide options for weight loss treatments. Following the successful release of our Semaglutide-based oral dissolvable tablet branded as SLIM, patients can choose from two advanced, highly effective GLP-1 receptor agonists, each tailored to meet different needs in their weight management journey. Both products are currently listed on the MangoRx website and available with a doctor’s prescription, providing expanded access to cutting-edge weight loss solutions through its telemedicine platform.
About MangoRx
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including: the market for, demand for, and efficacy of Tirzepatide and Semaglutide options for weight loss treatments; our ability to meet Nasdaq’s minimum bid price requirement and other continued listing requirements of Nasdaq, including the fact that the Company does not currently comply with Nasdaq’s minimum bid price requirement; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our products which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions and risks associated with related party relationships and agreements; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our products; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.
More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three and six months ended June 30, 2024, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow MangoRx on social media:
https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
FAQ
What is the new product launched by MangoRx (MGRX)?
How effective is Tirzepatide for weight loss according to clinical trials?
What is the projected growth of the GLP-1 market according to the MangoRx (MGRX) press release?
What weight loss products does MangoRx (MGRX) now offer through its telemedicine platform?
